Together, these findings indicate the overall heterogeneity of the mechanisms of responses to AR-targeted treatments in CRPC leading to tumor inhibition and, therefore, limitations to create a reliable response signature based on treatment-induced transcriptomic alterations. The gene discussed is AR; the disease is neoplasm.